Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
- Name
- Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
- Accession Number
- DBCAT003772 (DBCAT002659, DBCAT003469, DBCAT004600)
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Dapagliflozin A sodium-glucose cotransporter 2 inhibitor used in the management of type 2 diabetes mellitus. Canagliflozin A sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage hyperglycemia in type 2 diabetes mellitus (DM). Also used to reduce the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 DM. Ertugliflozin An SGLT2 inhibitor used to treat type 2 diabetes mellitus alone or in combination with other antidiabetic drugs. Ipragliflozin Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2. Sotagliflozin An orally administered dual SGLT1/2 inhibitor used alongside insulin to improve glycemic control in patients with type 1 diabetes mellitus. Empagliflozin An SGLT2 inhibitor used to manage type 2 diabetes mellitus. Luseogliflozin An SGLT2 inhibitor used to manage type 2 diabetes mellitus. Bexagliflozin A sodium-glucose co-transporter 2 inhibitor used to improve glycemic control in patients with type 2 diabetes mellitus. - Drugs & Drug Targets